Pembrolizumab (Keytruda®) in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of locally advanced, or early‑stage triple‑negative breast cancer (TNBC). Update September 2022

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of locally advanced, or early‑stage triple‑negative breast cancer (TNBC). Update September 2022. Oncology Fact Sheet Nr. 94.

[thumbnail of Oncology Fact Sheet Nr.94_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
131kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WP Gynaecology > WP 800-910 Breast
Language:	English
Series Name:	Oncology Fact Sheet Nr. 94
Deposited on:	16 May 2022 10:29
Last Modified:	10 Jul 2025 11:34

Repository Staff Only: item control page